Company intelligence / Profile preview

ZS Pharma

San Mateo, California, USAzs.com ↗

Ownership: Private
Employees: ~200
Development stage: NDA

Overview

ZS Pharma developed ZS‑9, a potential best-in-class treatment for hyperkalemia using proprietary ion-trap technology. Clinical trials demonstrated strong efficacy and safety. At the time of its acquisition by AstraZeneca in late 2015, the drug was under regulatory review with anticipated approval and market launch in mid-to-late 2016. The company had rapidly advanced from founding to IPO to late-stage clinical development within seven years.

Therapeutic areas: Nephrology
Modalities: Small molecules (specifically ion-trap technology for potassium binding)
Industry: Biotech

Drug pipeline

1 asset

ZS-9

NDA

Indications: Hyperkalemia, Chronic kidney disease, Chronic heart failure

Partnerships

UNT Health Science Center Accelerator Lab ProgramTech Fort Worth incubator support during early years

Beyond the preview

Go deeper on ZS Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZS Pharma.

Explore the full profile